Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study

Clinical Pharmacokinetics ◽

10.1007/s40262-021-01015-z ◽

2021 ◽

Author(s):

Joseph Chen ◽

Melissa T. O’Gorman ◽

Lee P. James ◽

Karen J. Klamerus ◽

Ganesh Mugundu ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Multiple Dosing ◽

Anaplastic Lymphoma ◽

1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(16)30245-3 ◽

2016 ◽

Vol 11 (4) ◽

pp. S114 ◽

Cited By ~ 16

Author(s):

R. Rosell ◽

S.N. Gettinger ◽

L.A. Bazhenova ◽

C.J. Langer ◽

R. Salgia ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib

Annals of Oncology ◽

10.1016/s0923-7534(20)32041-x ◽

2012 ◽

Vol 23 ◽

pp. xi44

Author(s):

P.-C. Yang ◽

R. Salgia ◽

B. Solomon ◽

A.T. Shaw ◽

D.R. Camidge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Visual Effects ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Nsclc Patients

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer

Cancer Management and Research ◽

10.2147/cmar.s173084 ◽

2018 ◽

Vol Volume 10 ◽

pp. 6555-6561 ◽

Cited By ~ 3

Author(s):

Ahmed Mohieldin ◽

Ayman Rasmy ◽

Mohamed Ashour ◽

Muath Al-Nassar ◽

Rola H Ali ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Advanced Stage ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma

PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.09.131 ◽

2019 ◽

Vol 14 (11) ◽

pp. S1171-S1172

Author(s):

T. Leal ◽

H. Wakelee ◽

K.L. Reckamp ◽

A. Chiappori ◽

G.R. Oxnard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Nsclc Patients

Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis

Journal of Clinical Pharmacy and Therapeutics ◽

10.1111/jcpt.13157 ◽

2020 ◽

Vol 45 (4) ◽

pp. 743-754 ◽

Cited By ~ 1

Author(s):

Wei Tian ◽

Ping Zhang ◽

Yuan Yuan ◽

Xiao‐Hui Deng ◽

Rui Yue ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma

P1.03-010 Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.814 ◽

2017 ◽

Vol 12 (11) ◽

pp. S1954

Author(s):

R. Imase ◽

S. Endo ◽

Y. Sasahara ◽

T. Shinmura ◽

T. Ozawa ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72076-0 ◽

2010 ◽

Vol 8 (7) ◽

pp. 117 ◽

Cited By ~ 3

Author(s):

B. Solomon ◽

Y.J. Bang ◽

D.R. Camidge ◽

A.J. Iafrate ◽

E.L. Kwak ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)

Annals of Oncology ◽

10.1093/annonc/mdz260.108 ◽

2019 ◽

Vol 30 ◽

pp. v653-v654 ◽

Cited By ~ 1

Author(s):

S. Popat ◽

G. Liu ◽

S. Lu ◽

G. Song ◽

V. Samnotra ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

10.1158/1538-7445.am2016-ct088 ◽

2016 ◽

Cited By ~ 1

Author(s):

Christine M. Lovly ◽

Jeffrey R. Infante ◽

George R. Blumenschein ◽

Karen Reckamp ◽

Heather Wakelee ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Inhibitor